Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H36N2O4 |
| Molecular Weight | 392.5322 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
| Stereo Comments | CIS |
SHOW SMILES / InChI
SMILES
CC(C)(N)CNC(=O)C[C@H]1CC[C@@]2(CC1)OO[C@@]3(O2)C4CC5CC(C4)CC3C5
InChI
InChIKey=VXYZBLXGCYNIHP-ACBWXVLLSA-N
InChI=1S/C22H36N2O4/c1-20(2,23)13-24-19(25)12-14-3-5-21(6-4-14)26-22(28-27-21)17-8-15-7-16(10-17)11-18(22)9-15/h14-18H,3-13,23H2,1-2H3,(H,24,25)/t14-,15?,16?,17?,18?,21-,22-
| Molecular Formula | C22H36N2O4 |
| Molecular Weight | 392.5322 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Arterolane is an anti-malarial drug developed by Ranbaxy Laboratories. Arterolane belongs to peroxidic antimalarial compounds. Upon administration, the drug is activated by heme of hemoglobin digested by malarial parasite. Activation produces free radicals, leading to alkylation of heme and proteins, critical for the survival of the parasite. Arterolane was approved for marketing in India in 2012 and received marketing authorization in several African countries in 2014.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Comparative embryotoxicity of different antimalarial peroxides: in vitro study using the rat whole embryo culture model (WEC). | 2010-12 |
|
| Arterolane, a new synthetic trioxolane for treatment of uncomplicated Plasmodium falciparum malaria: a phase II, multicenter, randomized, dose-finding clinical trial. | 2010-09-15 |
|
| The structure-activity relationship of the antimalarial ozonide arterolane (OZ277). | 2010-01-14 |
|
| Development and validation of a headspace gas chromatographic method for the determination of residual solvents in arterolane (RBx11160) maleate bulk drug. | 2010-01 |
|
| Simultaneous determination of OZ277, a synthetic 1,2,4-trioxolane antimalarial, and its polar metabolites in rat plasma using hydrophilic interaction chromatography. | 2009-10-01 |
|
| The future of artemisinins: natural, synthetic or recombinant? | 2008-12-15 |
|
| In vitro assessment of the pharmacodynamic properties of DB75, piperaquine, OZ277 and OZ401 in cultures of Plasmodium falciparum. | 2008-11 |
|
| Drug metabolism and pharmacokinetics. | 2008-10 |
|
| Characterization of the two major CYP450 metabolites of ozonide (1,2,4-trioxolane) OZ277. | 2008-03-01 |
|
| In vitro susceptibility of P. falciparum populations from Colombia and Tanzania to a new synthetic peroxide (OZ277). | 2007-06 |
|
| In vitro and in vivo interaction of synthetic peroxide RBx11160 (OZ277) with piperaquine in Plasmodium models. | 2007-03 |
|
| In vitro assessment of the pharmacodynamic properties and the partitioning of OZ277/RBx-11160 in cultures of Plasmodium falciparum. | 2006-07 |
|
| Plasmodium vivax: in vitro susceptibility of blood stages to synthetic trioxolane compounds and the diamidine DB75. | 2006-07 |
|
| Infectious diseases. Source of new hope against malaria is in short supply. | 2005-01-07 |
|
| [Artemisinin and successors]. | 2005 |
|
| Synthetic antimalaria drug enters clinical trials. | 2004-10 |
|
| Identification of an antimalarial synthetic trioxolane drug development candidate. | 2004-08-19 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:13:57 GMT 2025
by
admin
on
Mon Mar 31 19:13:57 GMT 2025
|
| Record UNII |
3N1TN351VB
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
P01BX02
Created by
admin on Mon Mar 31 19:13:57 GMT 2025 , Edited by admin on Mon Mar 31 19:13:57 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
5090
Created by
admin on Mon Mar 31 19:13:57 GMT 2025 , Edited by admin on Mon Mar 31 19:13:57 GMT 2025
|
PRIMARY | |||
|
C166684
Created by
admin on Mon Mar 31 19:13:57 GMT 2025 , Edited by admin on Mon Mar 31 19:13:57 GMT 2025
|
PRIMARY | |||
|
3N1TN351VB
Created by
admin on Mon Mar 31 19:13:57 GMT 2025 , Edited by admin on Mon Mar 31 19:13:57 GMT 2025
|
PRIMARY | |||
|
100000144464
Created by
admin on Mon Mar 31 19:13:57 GMT 2025 , Edited by admin on Mon Mar 31 19:13:57 GMT 2025
|
PRIMARY | |||
|
DTXSID50985095
Created by
admin on Mon Mar 31 19:13:57 GMT 2025 , Edited by admin on Mon Mar 31 19:13:57 GMT 2025
|
PRIMARY | |||
|
SUB121116
Created by
admin on Mon Mar 31 19:13:57 GMT 2025 , Edited by admin on Mon Mar 31 19:13:57 GMT 2025
|
PRIMARY | |||
|
8663
Created by
admin on Mon Mar 31 19:13:57 GMT 2025 , Edited by admin on Mon Mar 31 19:13:57 GMT 2025
|
PRIMARY | |||
|
136054
Created by
admin on Mon Mar 31 19:13:57 GMT 2025 , Edited by admin on Mon Mar 31 19:13:57 GMT 2025
|
PRIMARY | |||
|
664338-39-0
Created by
admin on Mon Mar 31 19:13:57 GMT 2025 , Edited by admin on Mon Mar 31 19:13:57 GMT 2025
|
PRIMARY | |||
|
ARTEROLANE
Created by
admin on Mon Mar 31 19:13:57 GMT 2025 , Edited by admin on Mon Mar 31 19:13:57 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT | |||
|
|
TARGET -> INHIBITOR |
EC50
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |